Regulation of the somatotropic axis by intensive insulin therapy during protracted critical illness.

The catabolic state of critical illness has been linked to the suppressed somatotropic GH-IGF-binding protein (IGFBP) axis. In critically ill patients it has been demonstrated that, compared with the conventional approach, which only recommended insulin therapy when blood glucose levels exceeded 12 mmol/liter, strict maintenance of blood glucose levels below 6.1 mmol/liter with intensive insulin therapy almost halved intensive care mortality, acute renal failure, critical illness polyneuropathy, and bloodstream infections. Poor blood glucose control in diabetes mellitus has also been associated with low serum IGF-I levels, which can be increased by insulin therapy. We hypothesized that intensive insulin therapy would improve the IGF-I axis, possibly contributing to the clinical correlates of anabolism. Therefore, this study of 363 patients, requiring intensive care for more than 7 d and randomly assigned to either conventional or intensive insulin therapy, examines the effects of intensive insulin therapy on the somatotropic axis. Contrary to expectation, intensive insulin therapy suppressed serum IGF-I, IGFBP-3, and acid-labile subunit concentrations. This effect was independent of survival of the critically ill patient. Concomitantly, serum GH levels were increased by intensive insulin therapy. The suppression of IGF-I in association with the increased GH levels suggests GH resistance induced by intensive insulin therapy, which was reflected by the decreased serum GH-binding protein levels. Intensive insulin therapy did not affect IGFBP-3 proteolysis, which was markedly higher in protracted critically ill patients compared with healthy controls. Also, intensive insulin therapy did not suppress the urea/creatinine ratio, a clinical correlate of catabolism. In conclusion, our data suggest that intensive insulin therapy surprisingly suppressed the somatotropic axis despite its beneficial effects on patient outcome. GH resistance accompanied this suppression of the IGF-I axis. To what extent and through which mechanisms the changes in the GH-IGF-IGFBP axis contributed to the survival benefit under intensive insulin therapy remain elusive.

[1]  S. Simpson.  Of Mice . . . , 2004, Science.

[2]  G. Brabant.  Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. , 2003, European journal of endocrinology.

[3]  T. Bek,et al.  Increased serum IGF-I during pregnancy is associated with progression of diabetic retinopathy. , 2003, Diabetes.

[4]  Miet Schetz,et al.  Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control* , 2003, Critical care medicine.

[5]  P. Sönksen,et al.  The role of the growth hormone–insulin‐like growth factor axis in glucose homeostasis , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[6]  G. Van den Berghe,et al.  Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. , 2002, The Journal of clinical endocrinology and metabolism.

[7]  Steven E Wolf,et al.  Hyperglycemia exacerbates muscle protein catabolism in burn-injured patients , 2002, Critical care medicine.

[8]  R. Wolfe,et al.  The effect of prolonged euglycemic hyperinsulinemia on lean body mass after severe burn. , 2002, Surgery.

[9]  W. Hop,et al.  Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors. , 2002, The Journal of clinical endocrinology and metabolism.

[10]  J. Holly,et al.  What is the role of the insulin‐like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? , 2002, Clinical endocrinology.

[11]  G. Van den Berghe,et al.  The combined administration of GH‐releasing peptide‐2 (GHRP‐2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP‐2 alone , 2002, Clinical endocrinology.

[12]  B. Bistrian,et al.  Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.

[13]  R. Baxter,et al.  How Should Insulin-Like Growth Factor I Be Measured? , 2004, Hormone Research in Paediatrics.

[14]  B A Mizock,et al.  Alterations in fuel metabolism in critical illness: hyperglycaemia. , 2001, Best practice & research. Clinical endocrinology & metabolism.

[15]  R. Baxter,et al.  Changes in the IGF-IGFBP axis in critical illness. , 2001, Best practice & research. Clinical endocrinology & metabolism.

[16]  C. Ohlsson,et al.  Liver-Derived IGF-I Regulates GH Secretion at the Pituitary Level in Mice. , 2001, Endocrinology.

[17]  O. Ljungqvist,et al.  Insulin infusion increases levels of free IGF-I and IGFBP-3 proteolytic activity in patients after surgery. , 2001, American journal of physiology. Endocrinology and metabolism.

[18]  C. Pichard,et al.  Management of catabolism in metabolically stressed patients: a literature survey about growth hormone application , 2001, Current opinion in clinical nutrition and metabolic care.

[19]  G. Ooi,et al.  The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. , 2001, The Journal of endocrinology.

[20]  J. Kopchick,et al.  Growth hormone receptor/binding protein (GHR/BP) knockout mice: a 3-year update. , 2001, Molecular genetics and metabolism.

[21]  D. Clemmons,et al.  Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. , 2000, Endocrinology.

[22]  R. Wolfe,et al.  Changes in Intermediary Metabolism in Severe Surgical Illness , 2000, World Journal of Surgery.

[23]  R. Baxter.  Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. , 2000, American journal of physiology. Endocrinology and metabolism.

[24]  Z. Hochberg,et al.  Clinical review 112: Does serum growth hormone (GH) binding protein reflect human GH receptor function? , 2000, The Journal of clinical endocrinology and metabolism.

[25]  J. Wernerman.  Protein wasting in severe illness: pathogenesis and therapy. , 2000, Diabetes, nutrition & metabolism.

[26]  E. Ruokonen,et al.  Dangers of growth hormone therapy in critically ill patients , 2000, Annals of medicine.

[27]  G. Van den Berghe,et al.  Increased mortality associated with growth hormone treatment in critically ill adults. , 2000, The New England journal of medicine.

[28]  G. Van den Berghe,et al.  A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. , 2000, The Journal of clinical endocrinology and metabolism.

[29]  J. Frystyk,et al.  Circulating levels of free insulin‐like growth factors in obese subjects: the impact of Type 2 diabetes , 1999, Diabetes/metabolism research and reviews.

[30]  D. Leroith,et al.  Normal growth and development in the absence of hepatic insulin-like growth factor I. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Van den Berghe,et al.  Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. , 1999, The Journal of clinical endocrinology and metabolism.

[32]  J. A. Scarlett,et al.  Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. , 1999, Diabetes.

[33]  C. Lang,et al.  Alterations in the Growth Hormone-Insulin-Like Growth Factor Axis in Insulin Dependent Diabetes Mellitus , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[34]  D. Chinkes,et al.  A submaximal dose of insulin promotes net skeletal muscle protein synthesis in patients with severe burns. , 1999, Annals of surgery.

[35]  R. Baxter,et al.  Thrity-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients , 1998 .

[36]  J. Fagin,et al.  Growth Hormone-Insulin-Like Growth Factor-I Axis in Adult Insulin-Dependent Diabetic Patients: Evidence for Central Hypersensitivity to Growth Hormone - Releasing Hormone and Peripheral Resistance to Growth Hormone , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[37]  O. Ljungqvist,et al.  Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity. , 1998, The Journal of clinical endocrinology and metabolism.

[38]  R. Baxter,et al.  Thirty-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients. , 1998, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[39]  R. Baxter.  The binding protein's binding protein--clinical applications of acid-labile subunit (ALS) measurement. , 1997, The Journal of clinical endocrinology and metabolism.

[40]  I. Robinson,et al.  Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat. , 1997, Endocrinology.

[41]  M. Rechler,et al.  Growth hormone stimulates transcription of the gene encoding the acid-labile subunit (ALS) of the circulating insulin-like growth factor-binding protein complex and ALS promoter activity in rat liver. , 1997, Molecular endocrinology.

[42]  J. Wernerman,et al.  Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: demonstration of reduced expression after elective surgery. , 1997, The Journal of clinical endocrinology and metabolism.

[43]  G. Van den Berghe,et al.  The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. , 1997, The Journal of clinical endocrinology and metabolism.

[44]  J. Holly,et al.  Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. , 1996, Critical care medicine.

[45]  R. Wolfe,et al.  Regulation of the acid‐labile subunit of the insulin‐like growth factor ternary complex in patients with insulin‐dependent diabetes mellitus and severe burns , 1996, Clinical endocrinology.

[46]  H. Michie,et al.  Metabolism of Sepsis and Multiple Organ Failure , 1996, World Journal of Surgery.

[47]  W. Blum,et al.  The differential regulation of the circulating levels of the insulin‐like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery , 1996, Clinical endocrinology.

[48]  R. Baxter,et al.  Insulin-like growth factor binding proteins as glucoregulators. , 1995, Metabolism: clinical and experimental.

[49]  C. Lang,et al.  Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. , 1995, The Journal of clinical endocrinology and metabolism.

[50]  G. Striker,et al.  Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. , 1995, Endocrinology.

[51]  R. Baxter,et al.  Regulation in vivo of the acid-labile subunit of the rat serum insulin-like growth factor-binding protein complex. , 1994, Endocrinology.

[52]  G. Van den Berghe,et al.  Growth hormone secretion in critical illness: effect of dopamine. , 1994, The Journal of clinical endocrinology and metabolism.

[53]  J. Wahren,et al.  Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. , 1994, The Journal of clinical endocrinology and metabolism.

[54]  K. Brismar,et al.  Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. , 1994, The Journal of clinical endocrinology and metabolism.

[55]  M. Binoux,et al.  Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. , 1994, Endocrinology.

[56]  D. Clemmons,et al.  Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery. , 1992, The Journal of clinical endocrinology and metabolism.

[57]  W. Tamborlane,et al.  Pituitary Response to Growth Hormone–Releasing Hormone in IDDM: Abnormal Responses to Insulin and Hyperglycemia , 1992, Diabetes.

[58]  J. Holly,et al.  Levels of GH binding activity, IGFBP‐1, insulin, blood glucose and cortisol in intensive care patients , 1991, Clinical endocrinology.

[59]  J. Holly,et al.  The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. , 1991, The Journal of endocrinology.

[60]  J. Miell,et al.  Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin–like growth factor‐I , 1991, Clinical endocrinology.

[61]  R. Baxter,et al.  Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. , 1990, The Journal of clinical endocrinology and metabolism.

[62]  A. Beddoe,et al.  Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. , 1987, The Journal of trauma.

[63]  J. H. Shaw,et al.  Whole Body Protein Kinetics in Severely Septic Patients: The Response to Glucose Infusion and Total Parenteral Nutrition , 1987, Annals of surgery.

[64]  R. Baxter,et al.  Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. , 1986, The Journal of clinical investigation.